BioNTech reports Q4 adjusted EPS EUR (0.33) vs. EUR 1.79 last year

Reports Q4 revenue EUR 907.4M vs. EUR 1.19B last year. “2025 was a year of strong execution and pipeline momentum, marked by substantial progress in delivering on our strategy. We advanced our oncology pipeline by moving multiple programs into late-stage development and initiated trials assessing novel-novel combination approaches with the aim of delivering differentiated therapeutic profiles,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech (BNTX). “With our unique pipeline and strong financial position, we remain committed to leveraging our pioneering position in the immuno-oncology space with next-generation agents designed to elevate outcomes for patients with cancer. 2026 is poised to be a pivotal year with multiple readouts expected across our portfolio, representing a significant step toward our objective of becoming a multi-product company by 2030.”